Versions
- 2023-02-07 (3)
- 2023-01-31 (2)
- 2022-06-30 (1)
Keywords
COVID-19
Skin reactions
South America
Vaccination
Abstract
Objective: To assess cutaneous reactions after Pfizer-BioNTech COVID-19 vaccine administration.
Methods: A cross-sectional observational study was carried out in health workers belonging to the city of Guayaquil-Ecuador, from March to May 2021. The participants were contacted through a local registry established by the Universidad Espíritu Santo. Frequencies and percentages were used to represent the proportions of nominal variables, while the mean and standard deviation were used for continuous data, given a normal sample distribution.
Results: Local skin reactions were the most frequent, and included redness, edema, and itching. On the other hand, delayed large local skin reactions (generalized rash and pruritus, angioedema, urticaria, eczema, petechiae) were rare and occurred in less than 1.4% of participants, (95% CI = 0.69-1.00). Finally, we did not find cases of anaphylaxis or other life-threatening reactions requiring urgent attention after vaccination.
Conclusions: Our findings suggest that local skin reactions occur in a minority of recipients and are often mild and self-limited.
References
Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics. 2021;11(4):579. DOI: 10.3390/diagnostics11040579.
COVID-19 vaccines. En: Drugs and Lactation Database (LactMed). EE. UU.: National Library of Medicine; 2021.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-416. DOI: 10.1056/NEJMoa2035389.
McMahon D, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A. E. et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55. DOI: 10.1016/j.jaad.2021.03.092
Robinson LB, Fu X, Hashimoto S, Wickner P, Sheoy ES, Landman AB, et al. Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines. JAMA Dermatol. 2021;157(8):1000-1002. DOI: 10.1001/jamadermatol.2021.2114
Shimabukoro T. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. Am J Transplant. 2021;21(3):1326-1331. DOI: 10.1111/ajt.16517
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. DOI: 10.1056/NEJMoa2034577
Razai MS, Chaudhry UA, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination hesitancy. BMJ. 2021;373:n1138. DOI: 10.1136/bmj.n1138
Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine. 2014;32(19):2150-2159. DOI: 10.1016/j.vaccine.2014.01.081
Solís-Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. Nat. Med. 2021;27(8):1385-1394. DOI: 10.1038/s41591-021-01454-y
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2022 Revista Alergia México